# Trend Investment Group

> Trend Investment Group is a VC fund backing Biotechnology, Health Care and Therapeutics. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 17
- Last investment: Jun 2024
- Lead investor: 6%
- Last updated: Aug 2026

Trend Investment Group is a VC fund focused on Biotechnology and Health Care. Trend Investment Group

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 47% |
| Health Care | 6 | 35% |
| Therapeutics | 5 | 29% |
| Pharmaceutical | 3 | 18% |
| Medical | 2 | 12% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 41% |
| Series B | 3 | 18% |
| Seed | 1 | 6% |
| Series C | 1 | 6% |
| Funding Round | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 6 | 35% |
| China | 3 | 18% |
| United States | 3 | 18% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hangmo Ouyi | Hangmo Ouyi is an automotive company that provides research, development, production, and sales of automotive drum brake pads, brake shoes, and disc brake pads with technical management and advanced formulation systems. Its mission is to establish in the domestic and overseas after-sales markets. |  | Series A | Jun 12, 2024 |  |
| Senisca | Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.8M |  | Mar 18, 2024 |  |
| Senisca | Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $4.7M | Seed | Mar 18, 2024 |  |
| Mogrify | Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via amulti-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. | $10M | Series A | Oct 02, 2023 |  |
| Astrocyte Pharmaceuticals | Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M | Series B | Aug 18, 2023 |  |
| MindImmune Therapeutics | MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated.Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs. | $12.4M | Series A | Jun 13, 2022 |  |
| Senisca | Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing. | $2.5M | Seed | Jun 09, 2022 |  |
| Pragmatic Semiconductor | Pragmatic is a ultra-low-cost flexible electronics. Their flexible integrated circuits (FlexICs) are thinner than human hair and can be invisibly embedded in objects, enabling innovators to create novel solutions to everyday problems that are not practical with conventional electronics.Designers can create their own application-specific flexibledevices using our FlexIC Foundry® service at a fraction of the cost and time required for traditional silicon circuits, opening up multiple new markets.We also offer standard FlexIC products that extend proven applications such as RFID and NFC into mass market use cases, enabling the potential for trillions of smart objects that can engage with consumers and their environments.All FlexICs are manufactured on our revolutionary FlexLogIC® production system, a highly scalable manufacturing model for cost-effective high-volume production, achieved with orders of magnitude lower capital investment and operating cost compared to a traditional silicon IC fab.Our novel, differentiated technology is being adopted by a growing base of global companies across diverse markets, including consumer goods, retail, healthcare, pharmaceutical, gaming and security.Pragmatic is headquartered in Cambridge, UK, with our first billion-unit production facility in Sedgefield. Shareholders include Cambridge Innovation Capital, Arm and Avery Dennison. | $5M | Series C | Jan 20, 2022 |  |
| Mogrify | Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via amulti-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. | $17M | Series A | May 04, 2021 |  |
| Astrocyte Pharmaceuticals | Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M | Series A | May 03, 2021 |  |

10 of 17 investments shown.

## Co-investors
- [QantX](https://shizune.co/investors/profile/qantx) — VC Fund, 5 deals together
- [APEX Ventures](https://shizune.co/investors/profile/apex-ventures-2) — VC Fund, 4 deals together
- [Emerging Longevity Ventures](https://shizune.co/investors/profile/emerging-longevity-ventures) — VC Fund, 4 deals together
- [R42 Group](https://shizune.co/investors/profile/r42-group) — VC Fund, 4 deals together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 3 deals together
- [Lifespan Vision Ventures](https://shizune.co/investors/profile/lifespan-vision-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Trend Investment Group invest in?

Trend Investment Group invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Trend Investment Group last invest?

The most recent investment recorded for Trend Investment Group closed in Jun 2024. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co